Lilli Stergiou is a Chemist and Molecular Biologist by training with over ten years of research experience in the field of prophylactic and therapeutic vaccines for infectious diseases, and in the oncology space. In her various roles in the biotech setting, she has been designing early-stage assets and working on the preclinical development of therapeutic candidates such as small molecules, peptides, nanoparticles, recombinant proteins and living microorganisms. Currently she’s serving as the CSO of Virometix where she’s building the company’s pipeline on vaccines and immunotherapies, based on synthetic virus-like particles and epitope mimetics.